Oluwakemi D. Alonge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oluwakemi D. Alonge has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Amy E. Hughes
Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
13 shared publications - Christine Neslund-Dudas
Henry Ford Health and Henry Ford Cancer Institute, Detroit, Michigan
13 shared publications - Christopher I. Li
Public Health Sciences Division Fred Hutchinson Cancer Center Seattle Washington USA
13 shared publications - Debra P. Ritzwoller
Institute for Health Research, Kaiser Permanente Colorado, Aurora, Colorado
13 shared publications - Douglas A. Corley
Division of Research, Kaiser Permanente Northern California, Oakland, California, USA
13 shared publications - Ethan A. Halm
Department of Medicine, Rutgers Robert Wood Johnson Medical School , New Brunswick, NJ 08901
13 shared publications
Latest Publications
- Open Access
- 21 November 2026
- Published by Springer Nature in Scientific Reports
The relationship between SARS-CoV-2 infection history and persistent symptoms in a rural Wisconsin community cohort
- 21 November 2026
- Published by Springer Nature in Scientific Reports
Open AccessThe relationship between SARS-CoV-2 infection history and persistent symptoms in a rural Wisconsin community cohort
- Open Access
- 3 November 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (11)
Coinfections With Respiratory Syncytial Virus in a Cohort of Adults With High‐Risk Conditions, 2015–2020: A Retrospective Observational Study
Summary: Coinfections may influence the clinical outcome of respiratory illness. Data are limited regarding RSV coinfections in adults with high‐risk conditions. Residual respiratory specimens from community‐dwelling adults (≥ 18 years) with ≥ 1 high‐risk condition were retested using a multiplex panel for multiple viral pathogens. We compared demographic and clinical characteristics between those with RSV coinfection versus RSV single infection. RSV coinfections comprised 5.9% of all RSV infections among adults with ≥ 1 high‐risk condition. No statistically significant differences were observed between those with RSV coinfections and single infections according to presence of specific high‐risk conditions or clinical disease presentation.
- 3 November 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (11)
Open AccessCoinfections With Respiratory Syncytial Virus in a Cohort of Adults With High‐Risk Conditions, 2015–2020: A Retrospective Observational Study
Summary: Coinfections may influence the clinical outcome of respiratory illness. Data are limited regarding RSV coinfections in adults with high‐risk conditions. Residual respiratory specimens from community‐dwelling adults (≥ 18 years) with ≥ 1 high‐risk condition were retested using a multiplex panel for multiple viral pathogens. We compared demographic and clinical characteristics between those with RSV coinfection versus RSV single infection. RSV coinfections comprised 5.9% of all RSV infections among adults with ≥ 1 high‐risk condition. No statistically significant differences were observed between those with RSV coinfections and single infections according to presence of specific high‐risk conditions or clinical disease presentation.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Background:Public health emergencies can substantially affect routine health care. Large cancer screening declines during the early months of the COVID-19 pandemic are well documented; however, COVID-19’s impact on follow-up of abnormal screening exams and cancer diagnoses is less reported. We examined the impacts of COVID-19 on the cervical, colorectal, and lung cancer screening processes, within 10 health systems in the Population-based Research to Optimize the Screening Process (PROSPR) consortium. Methods:PROSPR data were used to calculate: (i) monthly rates of cancer testing and, for pre-COVID and COVID time periods, (ii) proportions of individuals receiving recommended follow-up within 6 months of an abnormal test, and (iii) cancer incidence. Surveys were used to assess the healthcare systems’ local context. Results:During the first 2 months of the pandemic, cancer testing decreased across all health systems and cancer types (range, 18%–96%). Overall, decreases in monthly rates were followed by rapid recovery to prepandemic rates. The rates of 6-month follow-up of abnormal screening results trended down in the COVID versus pre-COVID periods, as did the diagnosis of new cancers. Conclusions:Declines in cancer testing in the early months of the COVID-19 pandemic were short term, with at least short-term impacts on diagnostic follow-up and cancer diagnosis. The systems with the smallest decreases were those that both utilized remote screening outreach (e.g., mailed fecal immunochemical test kits) and did not pause that outreach at the start of the pandemic. Impact:Strategies and policies implemented by healthcare systems during public health emergencies can help minimize disruptions in care.See related In the Spotlight, p. 1481
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Background:Public health emergencies can substantially affect routine health care. Large cancer screening declines during the early months of the COVID-19 pandemic are well documented; however, COVID-19’s impact on follow-up of abnormal screening exams and cancer diagnoses is less reported. We examined the impacts of COVID-19 on the cervical, colorectal, and lung cancer screening processes, within 10 health systems in the Population-based Research to Optimize the Screening Process (PROSPR) consortium. Methods:PROSPR data were used to calculate: (i) monthly rates of cancer testing and, for pre-COVID and COVID time periods, (ii) proportions of individuals receiving recommended follow-up within 6 months of an abnormal test, and (iii) cancer incidence. Surveys were used to assess the healthcare systems’ local context. Results:During the first 2 months of the pandemic, cancer testing decreased across all health systems and cancer types (range, 18%–96%). Overall, decreases in monthly rates were followed by rapid recovery to prepandemic rates. The rates of 6-month follow-up of abnormal screening results trended down in the COVID versus pre-COVID periods, as did the diagnosis of new cancers. Conclusions:Declines in cancer testing in the early months of the COVID-19 pandemic were short term, with at least short-term impacts on diagnostic follow-up and cancer diagnosis. The systems with the smallest decreases were those that both utilized remote screening outreach (e.g., mailed fecal immunochemical test kits) and did not pause that outreach at the start of the pandemic. Impact:Strategies and policies implemented by healthcare systems during public health emergencies can help minimize disruptions in care.See related In the Spotlight, p. 1481
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Figure S1. Cervical cancer testing rates by health system, modality, and background COVID incidence.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Figure S1. Cervical cancer testing rates by health system, modality, and background COVID incidence.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Figure S2. Colorectal cancer testing rates by health system, modality, and background COVID incidence.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Figure S2. Colorectal cancer testing rates by health system, modality, and background COVID incidence.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Figure S3. Lung cancer testing rates by health system, modality, and background COVID incidence.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Figure S3. Lung cancer testing rates by health system, modality, and background COVID incidence.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Figure S4. Cumulative incidence of follow-up after abnormal cervical cancer test, by health system and pre-COVID/COVID time period.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Figure S4. Cumulative incidence of follow-up after abnormal cervical cancer test, by health system and pre-COVID/COVID time period.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Figure S6. Cumulative incidence of follow-up after abnormal LDCT, by health system and pre-COVID/COVID time period.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Figure S6. Cumulative incidence of follow-up after abnormal LDCT, by health system and pre-COVID/COVID time period.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Figure S5. Cumulative incidence of follow-up after abnormal FIT/gFOBT, by health system and pre-COVID/COVID time period.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Figure S5. Cumulative incidence of follow-up after abnormal FIT/gFOBT, by health system and pre-COVID/COVID time period.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Table S2. Patient characteristics by health system (cervical).
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: An Evaluation of the COVID-19 Pandemic
Supplementary Table S2. Patient characteristics by health system (cervical).